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Abstract 
 
This paper examines and contrasts the legal framework in the United States and 
comparable  legislation  in  Taiwan.  Prompted  by  the  Syntex  incident,  the  U.S. 
Congress passed the Infant Formula Act of 1980, and delegated the Food and Drug 
Administration (FDA) the authority to establish the regulations in order to safeguard 
the health of infant children. In contrast to the legislation history in the United States, 
Taiwan enacted the comparable law and established relevant regulations late in 2008. 
A comparison of these two legal systems reveals that the United States has a more 
comprehensive regulatory scheme for infant formula, while Taiwan focuses only on 
the sanitary conditions for infant formula manufacture. Besides, U.S. infant formula 
regulations have expanded and become more stringent while Taiwan’s FDA (TFDA) 
only requires manufacturers to meet certain sanitary requirements, without mandating 
how to achieve them. Another difference is that the U.S. FDA does not require infant 
formula  manufacturers  to  note  that  breastfeeding  is  more  nutritious  than  infant 
formula on their product labels, but TFDA takes a firm stance and requires formula 
manufacturers  to  state  on  product  labels  that  breast  milk  is  more  nutritious  than 
formula. 
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Infant Formula: 
A Comparison of Legislation in the United States and Taiwan 
Introduction	 ﾠ
The  first  year  of  human  life  is  marked  by  rapid  development  ―  cognitive, 
physical, social, and emotional. Infants double their weight between birth and four 
months and triple it by the age of one.
1  Thus, infants’ nourishment, whether it is 
breast milk or infant formula, plays an important role in their development, and thus, 
the quality of infant formula on the market can greatly influence the long-term health 
and welfare of a nation’s populace. While technological development has improved 
living conditions worldwide, it has also changed basic, traditional, healthy practices 
such as breast feeding. Over the past half century, increasing numbers of women have 
entered the workplace, which has subsequently decreased breastfeeding practices.
2   
  For bottle-fed infants, infant formula is the sole source of nutrition to support 
their growth and development up to six months of age because their gastrointestinal 
and renal systems have not matured enough to digest other foods and fully absorb 
their nutrition. As a result, infant formula needs to be specially formulated so as to 
match  the  nutrients  and  qualities  of  mothers’  milk  to  enable  infants  to  receive 
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1	 ﾠ Sue	 ﾠAnn	 ﾠAnderson	 ﾠet	 ﾠal.,	 ﾠHistory	 ﾠand	 ﾠCurrent	 ﾠStatus	 ﾠof	 ﾠInfant	 ﾠFormulas,	 ﾠ35	 ﾠThe	 ﾠAmerican	 ﾠSociety	 ﾠfor	 ﾠ
Clinical	 ﾠNutrition,	 ﾠ381,	 ﾠ387(1982).	 ﾠ
2	 ﾠ Martha	 ﾠA.	 ﾠToll,	 ﾠSpilled	 ﾠ“Milk”:	 ﾠA	 ﾠRebuttal	 ﾠto	 ﾠthe	 ﾠUnited	 ﾠStates	 ﾠVote	 ﾠagainst	 ﾠthe	 ﾠInternational	 ﾠCode	 ﾠof	 ﾠ
Marketing	 ﾠof	 ﾠBreast-ﾭ‐Milk	 ﾠSubstitutes,	 ﾠ2	 ﾠB.U.	 ﾠInt’l	 ﾠL.	 ﾠJ.	 ﾠ103,	 ﾠ105(1983-ﾭ‐1984).	 ﾠ2	 ﾠ
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adequate  nutrition.  Based  on  this  unique  status,  in  1981,  the  Codex  Alimentarius 
Commission,  part  of  both  the  Food  and  Agriculture  Organization  of  the  United 
Nations (FAO) and the World Health Organization, developed standards on infant 
formula.
3  Therefore, more and more countries have realized that they need to regulate 
the manufacture, quality and sale of infant formula to protect their future generation. 
  This paper compares and contrasts the legal framework in the United States, 
which enacted the Infant Formula Act in 1980, and comparable legislation in Taiwan, 
which did not implement a similar act until 2008. Besides, this paper also examines 
the regulations established by the U.S. the Food and Drug Administration (FDA) and 
Taiwan’s FDA (TFDA), and analyzes how it influences the practice of infant feeding 
in two countries.	 ﾠ Based	 ﾠ on	 ﾠ the	 ﾠ Center of Disease Control National Immunization 
Survey, in 2004, 42.1% of six month old infants in the United States were breastfed, 
and in 2008, 44.3% were breast fed
4. The practice of infant feeding in the United 
States seems static. In contrast, in Taiwan, breastfeeding largely increased during the 
recent years; in 2004, only 19.82% of six month old infants were breastfed, but by 
2011, 50.4% were breastfed
5. It implies that the recent legislation and regulation in 
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3	 ﾠ Berthold	 ﾠKoletzko,	 ﾠStandards	 ﾠfor	 ﾠInfant	 ﾠFormula	 ﾠMilk,	 ﾠ332	 ﾠBritish	 ﾠMedical	 ﾠJournal	 ﾠ621,	 ﾠ622	 ﾠ(2006)	 ﾠ
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1403284/	 ﾠ
4	 ﾠ Centers	 ﾠfor	 ﾠDisease	 ﾠControl	 ﾠand	 ﾠPrevention,	 ﾠBreastfeeding	 ﾠAmong	 ﾠU.S.	 ﾠChildren	 ﾠBorn	 ﾠ2000—2008,	 ﾠ
CDC	 ﾠNational	 ﾠImmunization	 ﾠSurvey,	 ﾠCENTERS	 ﾠFOR	 ﾠDISEASE	 ﾠCONTROL	 ﾠAND	 ﾠPREVENTION	 ﾠ
http://www.cdc.gov/breastfeeding/data/NIS_data/index.htm	 ﾠ(last	 ﾠupdated:	 ﾠAugust	 ﾠ1,	 ﾠ2011)	 ﾠ
5	 ﾠ Bureau	 ﾠof	 ﾠHealth	 ﾠPromotion,	 ﾠBreastfeeding	 ﾠStatistics,	 ﾠBUREAU	 ﾠOF	 ﾠHEALTH	 ﾠPROMOTION	 ﾠ(Mar.	 ﾠ15	 ﾠ
2012)	 ﾠhttp://www.bhp.doh.gov.tw/breastfeeding/02qna_01.htm	 ﾠ3	 ﾠ
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Taiwan  may  have  a  strong  impact  on  this  change.  This  paper  also  examines  the 
political forces that led to the enactment of these two different frameworks. 
The forms of legislation and regulations that insure the nutrition and safety of 
infant  formula  reflect  not  only  the  attitude  of  a  nation  toward  its  “most  precious 
resource – infant children”
6, but also its distinctive national values. A comparison of 
these  two  legal  systems  reveals  that  the  United  States  has  a  more  comprehensive 
regulatory scheme for infant formula, while Taiwan’s falls short and focuses only on 
the  sanitary  conditions  for  infant  formula  manufacture.  Furthermore,  U.S.  infant 
formula  regulations  have  expanded  and  become  more  stringent  since  1980,  while 
TFDA, which suppresses infant formula sales, only requires manufacturers to meet 
certain  sanitary  requirements,  without  mandating  how  to  achieve  them.  Another 
difference is that the U.S. FDA does not require infant formula manufacturers to note 
that breastfeeding is more nutritious than infant formula on their product labels, but 
TFDA takes a firm stance and requires formula manufacturers to state on product 
labels that breast milk is more nutritious than formula. 
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6	 ﾠ Infant	 ﾠFormula:	 ﾠHearing	 ﾠbefore	 ﾠthe	 ﾠSubcomm.	 ﾠon	 ﾠOversight	 ﾠand	 ﾠInvestigations	 ﾠof	 ﾠthe	 ﾠComm.	 ﾠon	 ﾠ
Interstate	 ﾠand	 ﾠForeign	 ﾠCommerce,	 ﾠ96th	 ﾠCong.	 ﾠ1	 ﾠ(1979).	 ﾠ4	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The	 ﾠU.S.	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980	 ﾠ
Motivation	 ﾠfor	 ﾠIts	 ﾠEnactment:	 ﾠThe	 ﾠSyntex	 ﾠIncident	 ﾠ
In 1979, two infant formulas, Neo-Mull-Soy and Cho-Free, both manufactured 
by Syntex Laboratories of California, were found to be greatly deficient in chloride, a 
chemical nutrient vital to infant development. According to a Committee on Labor 
and Human Resources report, although no infants died from consuming these two 
infant formulas, “over 130 infants who had consumed the formula suffered injury 
from  potentially  lethal  and  rare  chemical  imbalance  in  the  blood  known  as 
hypochloremic metabolic alkalosis.”
7   
This tragedy was brought to light by pediatric nephrologist Dr. Shane Roy of the 
University  of  Tennessee.
8  In  1979,  Dr.  Roy  discovered  that  three  infants  he  was 
treating for failure to develop normally were fed Neo-Mull Soy, a synthetic soy-based 
infant  formula  manufactured  by  Syntex  Corporation  of  Palo  Alto  California.    He 
called Syntex to check if they had any reported problems and was told they had none. 
He had the formula assayed, which showed that the chloride component was two 
milliequivalents per liter, only one-third of whatthe production information showed it 
should contain.
9  Besides notifying Syntex, Dr. Roy also informed the county public 
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7	 ﾠ Comm.	 ﾠOn	 ﾠLabor	 ﾠand	 ﾠHuman	 ﾠResources,	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980,	 ﾠS.	 ﾠREP.	 ﾠNo.	 ﾠ96-ﾭ‐916,	 ﾠat	 ﾠ5	 ﾠ(1980)	 ﾠ
8	 ﾠ Randal	 ﾠD.	 ﾠShields,	 ﾠFood	 ﾠand	 ﾠDrug	 ﾠLaw:	 ﾠThe	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980,	 ﾠ15	 ﾠAkron	 ﾠL.	 ﾠRev.	 ﾠ752,	 ﾠ753	 ﾠ
(1981-ﾭ‐1982).	 ﾠ
9	 ﾠ The	 ﾠSubcomm.	 ﾠon	 ﾠOversight	 ﾠand	 ﾠInvestigations	 ﾠof	 ﾠthe	 ﾠComm.	 ﾠon	 ﾠInterstate	 ﾠand	 ﾠForeign	 ﾠCommerce,	 ﾠ5	 ﾠ
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health department, which reported this to the Centers for Disease Control (CDC) in 
Atlanta.
10  The  CDC  then  conducted  a  national  review  and  found  that  among  27 
reported metabolic alkalosis cases in which a feeding history was available, 26 infants 
were on Neo-Mull-Soy (made by Syntex Laboratories of Palo Alto, California), the 
same  formula  consumed  by  babies  in  the  three  index  cases  reported  by  Dr.  Roy 
(CDC).  The  CDC  then  reported  this  to  the  FDA.
11  During  a  subsequent  hearing 
before  the  subcommittee  of  the  Oversight  and  Investigations  Committee  in  the 
summer of 1979, Dr. Roy testified that he had treated three infants, all of whom had 
failed to develop at normal rates. On August 1
st, Syntex Corporation of Palo Alto, 
California, at the request of the FDA, initiated a voluntary and low-key recall of Neo- 
Mull-Soy infant formula.
12 
Subsequent  investigations  carried  out  by  the  U.S.  Senate’s  Subcommittee  on 
Oversight and Investigation of the Comm. on Interstate and Foreign Commerce, and 
the Subcommittee on Health and Scientific Research of the Committee on Labor, 
concluded that multiple factors led to this tragedy:
13 
•  Syntex Cooperation failed to establish an adequate quality-control procedure 
to  assure  that  the  infant  formulas  contained  necessary  nutrients  as 
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supra	 ﾠnote	 ﾠ5,	 ﾠat	 ﾠ6-ﾭ‐7.	 ﾠ
10	 ﾠ Id.	 ﾠat	 ﾠ7.	 ﾠ
11	 ﾠ Id.	 ﾠat	 ﾠ9.	 ﾠ
12	 ﾠ Id.	 ﾠat	 ﾠ2.	 ﾠ
13	 ﾠ Comm.	 ﾠOn	 ﾠLabor	 ﾠand	 ﾠHuman	 ﾠResource,	 ﾠsupra	 ﾠnote	 ﾠ6,	 ﾠat	 ﾠ3-ﾭ‐4.	 ﾠ6	 ﾠ
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recommended by the American Pediatric Association.   
•  The FDA had not listed chloride in its catalog of vital nutrients for infant 
formula,  ignoring  the  1976  recommendation  of  the  American  Academy 
Pediatrics. 
•  The FDA failed to implement and monitor an immediate and complete recall 
of  Neo-Mull-Soy  and  Cho-Free  infant  formulas,  which  were  still  on  the 
market three months after the start of the voluntary recall. 
•  Syntex did not fully cooperate with the FDA to fully recall and oversee the 
recall of Neo-Mull-Soy and Cho-Free formulas.     
Actually, Neo-Mull-Soy and Cho-Free were not the only two infant formulas that 
were recalled by manufacturers in 1979. In the same year, four infant formulas were 
recalled  —  Neo-Mull-Soy,  Cho-Free  and  Soyalac,  manufactured  by  Loma  Linda 
Foods, were recalled because of lack of adequate amounts of chloride, and SMA, 
manufactured by Wyeth Laboratories, was recalled due to the poor processing which 
caused many infants sick.
14  As a result, parents’ confidence in commercial infant 
formulas was severely shaken, and the need for legislation to safeguard the quality 
and  safety  of  infant  formulas  prompted  the  U.S.  House  of  Representatives 
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14	 ﾠ Infant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980:	 ﾠHearing	 ﾠbefore	 ﾠthe	 ﾠSubcomm.	 ﾠon	 ﾠHealth	 ﾠand	 ﾠScientific	 ﾠResearch	 ﾠof	 ﾠthe	 ﾠ
Comm.	 ﾠOn	 ﾠLabor	 ﾠand	 ﾠHuman	 ﾠResources,	 ﾠ96th	 ﾠCong.	 ﾠ1	 ﾠ(1980).	 ﾠ7	 ﾠ
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Subcommittee on Oversight and Investigations of the Committee on Interstate and 
Foreign Commerce, in November 1979 to immediately enact legislation to:
15   
•  Create a separate category of food designated as “infant formula”, to include 
products intended to provide a nutritionally adequate diet to infants. 
•  Require that infant formulas contain all nutrients recognized as essential by 
the American Pediatric Association. 
•  Require  that  all  products  labeled  “infant  formula”  contain  the  essential 
nutrients. 
•  Require that all infant formulas be tested for their nutritional adequacy before 
marketing  and  after  any  changes  made  in  the  formula  or  manufacturing 
process. 
•  Require that recalls of infant formula be conducted as FDA Class I recalls, 
which indicate a potential for serious adverse health consequences or death. 
•  Grant the FDA the authority in infant formula recall situations to inspect a 
manufacturer’s records and to enforce compliance with recall directives. 
•  Require that 100 percent of consignees be contacted during infant formula 
recalls, a procedure that the FDA defines as a “Level A effectiveness check”.     
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 ﾠ Id.	 ﾠat	 ﾠ5.	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The	 ﾠContent	 ﾠof	 ﾠthe	 ﾠ1980	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠ
Pushed by the urgent need of legislation following the Syntex case, the U.S. 
House passed the bill on 20
th May 1980, which the Senate subsequently amended and 
passed on 8th September, 1980; the House immediately concurred on the Senate’s 
amendment on 9
th September 1980, which resulted in the Infant Formula Act (HR 
6940, Public Law 96-359), signed into the law by President Jimmy Carter on 26
th 
September  1980.
16  In  signing  the  Act,  President  Carter  said,  “This  legislation 
recognizes that our most important resource for the future ― our children ― should 
be  afforded  safe  and  nutritionally  adequate  formulas  during  a  critical  period  of 
development.”
17   
The Infant Formula Act creates a unique legal category of food designated as 
“infant formula”. According to 21 U.S.C §321 (aa), the term infant formula is “a food 
which purports to be or is represented for special dietary use solely as food for infants 
by reason of its simulation of human milk or its suitability as a complete or partial 
substitute  for  human  milk.”  It  specifies  minimums,  and  some  maximums,  of  the 
amount  of  protein,  fat,  essential  fatty  acids,  vitamins,  and  minerals  and  their 
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16	 ﾠ Infant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980,	 ﾠPub.	 ﾠL.	 ﾠNo.	 ﾠ96-ﾭ‐359,	 ﾠ94	 ﾠStat.	 ﾠ1190,	 ﾠ1195	 ﾠ(1980)	 ﾠ(codified	 ﾠas	 ﾠamended	 ﾠat	 ﾠ
21	 ﾠU.S.C	 ﾠ301).	 ﾠ
17	 ﾠ Jimmy	 ﾠCarter,	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980	 ﾠStatement	 ﾠon	 ﾠSigning	 ﾠH.R.	 ﾠ6940	 ﾠInto	 ﾠLaw,	 ﾠTHE	 ﾠAMERICAN	 ﾠ
PRESSIDENCY	 ﾠPROJECT,	 ﾠhttp://www.presidency.ucsb.edu/ws/index.php?pid=45151#axzz1pPvknqBM	 ﾠ
(last	 ﾠvisited:	 ﾠMar.	 ﾠ17,	 ﾠ2012)	 ﾠRead	 ﾠmore	 ﾠat	 ﾠthe	 ﾠAmerican	 ﾠPresidency	 ﾠProject:	 ﾠwww.presidency.ucsb.edu	 ﾠ
http://www.presidency.ucsb.edu/ws/index.php?pid=45151#ixzz1pPxW6qU0	 ﾠ9	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densities.
18  In  view  of  development  of  knowledge  of  nutrients  and  health,  it  also 
grants the Secretary of Health and Human Services Dept. authority to revise the list of 
nutrients and their required densities and levels for infant formula when necessary.
19 
In addition, to assure the safety of infant formulas, the Secretary is empowered to 
establish quality factors
20, quality control procedures
21, recall requirements
22, record 
keeping
23  and any infant formula exemptions for special types of infant formulas 
24 
under  the  Infant  Formula  Act.  If  an  infant  formula  fails  to  contain  the  required 
nutrients  or  meet  the  quality  requirements,  or  if  a  company  fails  to  process  the 
formula  in  compliance  with  the  quality  control  requirements,  it  will  be  deemed 
adulterated.
25 
The U.S. Congress set definite nutrient requirements for infant formulas, rather 
than  grant  the  FDA  comprehensive  authority  to  make  these  rules,  apparently 
responding to the urgent need to set clear criteria for the FDA’s implementation.
26 
The Committee on Labor and Human Resources persuaded Congress that “it would be 
an irresponsible public policy to permit the effective establishment of formula safety 
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18	 ﾠ Infant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980,	 ﾠsupra	 ﾠnote	 ﾠ17	 ﾠSec.	 ﾠ412.	 ﾠ(a)(1)(A),	 ﾠ(g).	 ﾠ
19	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(a)(2)(A),	 ﾠ(B).	 ﾠ
20	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(a)(2)(C).	 ﾠ
21	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(	 ﾠa)(2)(D).	 ﾠ
22	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(d)(2).	 ﾠ
23	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(e)(2).	 ﾠ
24	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(f)(2).	 ﾠ
25	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(a)(1).	 ﾠ
26	 ﾠ Toby	 ﾠMilgrom	 ﾠLevin,	 ﾠThe	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980:	 ﾠA	 ﾠCase	 ﾠStudy	 ﾠof	 ﾠCongressional	 ﾠDelegation	 ﾠto	 ﾠ
the	 ﾠFood	 ﾠand	 ﾠDrug	 ﾠAdministration,	 ﾠ42	 ﾠFood	 ﾠDrug	 ﾠCosm.	 ﾠL.	 ﾠJ.	 ﾠ101,114(1987.)	 ﾠ10	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and  quality  standards  to  be  delayed  one  or  two  years  due  to  the  procedural 
requirements  of  the  rule  making  process.”
27  Thus,  Congress  accepted  the  1976 
recommendation of the American Academy of Pediatrics to list all required nutrients 
in the nutrient table in the Act, and ask the Secretary of Health and Human Services to 
work  in  concert  with  the  Committee  on  Nutrition  of  the  American  Academy  of 
Pediatrics  (CON/AAP),  the  infant  formula  industry,  the  Codex  Alimentarius 
Commission and others to update the nutrient table in the Act regularly. Later, in 
October 1985, referring to the 1983 recommendation of CON/AAP and the Codex 
Alimentarius  Commission’s  International  Standard  of  Infant  Formula,  the  FDA 
updated the nutrient requirements of infant formula.
28   
n  Under  subsection  (c)(1)  of  the  Act,  infant  formula  manufacturers  must 
promptly notify the Secretary of HHS if they have reasonable knowledge 
that  their  formula  does  not  contain  nutrients  in  compliance  with  those 
required under the FDA, or may be otherwise adulterated or misbranded, 
and could jeopardize human health.
29  Further, under subsection (b)(3), after 
a manufacturer changes a formula’s ingredients or percentage of ingredients, 
or  processing,  changes  that  the  manufacturer  can  reasonably  determine 
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27	 ﾠ The	 ﾠSubcomm.	 ﾠon	 ﾠHealth	 ﾠand	 ﾠScientific	 ﾠResearch	 ﾠof	 ﾠthe	 ﾠComm.	 ﾠon	 ﾠLabor	 ﾠand	 ﾠHuman	 ﾠResources,	 ﾠ
supra	 ﾠnote	 ﾠ13,	 ﾠat	 ﾠ21.	 ﾠ
28	 ﾠ Nutrient	 ﾠRequirements	 ﾠfor	 ﾠInfant	 ﾠFormulas,	 ﾠ50	 ﾠFed.	 ﾠReg.	 ﾠ45,106,	 ﾠ108(Oct.	 ﾠ30,	 ﾠ1985)(to	 ﾠbe	 ﾠcodified	 ﾠ
at	 ﾠ21	 ﾠC.F.R	 ﾠPt.	 ﾠ107)	 ﾠ
29	 ﾠ Infant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980,	 ﾠsupra	 ﾠnote	 ﾠ15,	 ﾠSec.	 ﾠ412.	 ﾠ(c)(1).	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could influence whether the formula is adulterated, the manufacturer should 
notify the Secretary that: 
n  The nutrients in the infant formula meet the standards in the nutrient table in 
the Act.   
n  The infant formula complies with the FDA’s quality factor requirements. 
n  The  infant  formula  processing  conforms  to  the  FDA’s  quality  control 
procedure.
30 
The  addition  of  these  notification  provisions  could  be  Congress’s  response  to  the 
Syntex incident, which many people believed was caused by the FDA’s failure to 
monitor the nutrient levels in infant formula, which led to the 1979 tragedy.
31 
However, under the Infant Formula Act, the FDA does not have the power to mandate 
infant formula recalls. The initiation of a recall remains up to the manufacturer’s 
discretion. Nonetheless, the FDA can establish the scope and extent of the recall.
32 
There  is  a  time  limit  of  days  after  the  beginning  of  a  recall  and  every  15  days 
afterwards  until  the  recall  is  completed
33,  allowing  FDA  to  review  whether  the 
manufacturer conforms to the regulations. 
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 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(b)(3).	 ﾠ
31	 ﾠ Randal	 ﾠD.	 ﾠShields,	 ﾠFood	 ﾠand	 ﾠDrug	 ﾠLaw:	 ﾠthe	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980,	 ﾠ15	 ﾠAkron	 ﾠL.	 ﾠRev.	 ﾠ752,	 ﾠ
755(1981-ﾭ‐1982).	 ﾠ
32	 ﾠ Infant	 ﾠFormula	 ﾠAct	 ﾠof	 ﾠ1980,	 ﾠsupra	 ﾠnote	 ﾠ15	 ﾠSec.	 ﾠ(d)(2).	 ﾠ
33	 ﾠ Id.	 ﾠSec.	 ﾠ412.	 ﾠ(d)(1).	 ﾠ12	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The	 ﾠ1986	 ﾠAmendment	 ﾠto	 ﾠthe	 ﾠInfant	 ﾠFormula	 ﾠAct	 ﾠ 	 ﾠ 	 ﾠ
Although the U.S. Congress, in establishing the Infant Formula Act of 1980, 
granted the FDA authority to establish regulations relating to infant formula nutrient 
requirements, quality control procedures, labeling requirements, exemption status, and 
recalls, it was not satisfied with the consequent regulations set by the FDA. Moreover, 
in  early  1982  a  vitamin  B6-deficient  Nursoy  concentrated  liquid  and  Nursoy 
ready-to-feed  infant  formula,  manufactured  by  Wyeth  Laboratories,  shattered  the 
public’s already fragile confidence in infant formula.
34  Thus, Congress took another 
step to specify the level of the FDA’s regulatory control so as to better protect the 
public health.
35  Consequently, the 1986 Amendment was passed by both the House 
and the Senate and signed by President Ronald Reagan on 27
th October 1986. 
The 1986 amendment modified the Infant Formula Act of 1980, by:
36 
l  Deeming an infant formula to be adulterated unless it provides certain required 
nutrients, meets the quality requirements established by the Secretary of Health 
and  Human  Services  and  is  manufactured  in  accordance  with  Current  Good 
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34	 ﾠ Infant	 ﾠFormula:	 ﾠthe	 ﾠPresent	 ﾠDanger:	 ﾠHearing	 ﾠbefore	 ﾠthe	 ﾠSubcomm.	 ﾠon	 ﾠOversight	 ﾠand	 ﾠInvestigations	 ﾠ
of	 ﾠthe	 ﾠComm.	 ﾠon	 ﾠEnergy	 ﾠand	 ﾠCommerce	 ﾠ,	 ﾠ97th	 ﾠCong.	 ﾠ10-ﾭ‐11	 ﾠ(1982).	 ﾠ
35	 ﾠ Toby	 ﾠMilgrom	 ﾠLevin,	 ﾠsupra	 ﾠnote	 ﾠ24	 ﾠ,118.	 ﾠ
36	 ﾠ Infant	 ﾠFormula	 ﾠAct	 ﾠAmendment	 ﾠof	 ﾠ1986,	 ﾠPub.	 ﾠL.	 ﾠNo.	 ﾠ99-ﾭ‐570,	 ﾠ100	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 ﾠ116,	 ﾠ(1980)	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as	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 ﾠat	 ﾠ21	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 ﾠ301)	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Manufacturing Processes (CGMP) and quality control procedures established by 
the Secretary of Health and Human Services; 
l  Requiring  that  the  Secretary  issue  regulations  establishing  requirements  for 
quality factors and CGMP, including quality control procedures;   
l  Requiring that infant formula manufacturers regularly audit and examine their 
operations  to  ensure  that  they  comply  with  CGMP  and  quality  control 
regulations;   
l  Expanding the circumstances in which manufacturers must make a submission to 
notify  the  FDA  to  include  when  a  manufacturer  makes  major  changes  in  an 
infant formula, and when a manufacturer makes changes that may affect whether 
the formula is adulterated;   
l  Specifying the nutrient quality control testing required on each batch of infant 
formula;   
l  Modifying the infant formula recall requirements; and 
l  Giving the Secretary authority to establish requirements for retention of records, 
including records necessary to demonstrate compliance with CGMP and quality 
control procedures.
37 
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37	 ﾠ Current	 ﾠGood	 ﾠManufacturing	 ﾠPractices,	 ﾠQuality	 ﾠControl	 ﾠProcedures,	 ﾠQuality	 ﾠFactors,	 ﾠNotification	 ﾠ
Requirements,	 ﾠand	 ﾠRecords	 ﾠand	 ﾠReports,	 ﾠfor	 ﾠthe	 ﾠProduction	 ﾠof	 ﾠInfant	 ﾠFormula,	 ﾠ61	 ﾠFed.	 ﾠReg.	 ﾠ14	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FDA	 ﾠregulations	 ﾠrelating	 ﾠto	 ﾠinfant	 ﾠformula	 ﾠ
In  1982,  the  FDA  delegated  through  the  Infant  Formula  Act  adopted  Infant 
Formula Recall Procedures in subpart D of 21 CFR part 107 of its regulations
38  and 
Infant Formula Quality Control Procedures in subpart B of 21 CFR part 106
39. In 
1985, the FDA further implemented the Infant Formula Act by establishing subparts 
B
40, C
41, and D
42  in 21 CFR part 107 regarding the labeling of infant formula, exempt 
infant formulas, and nutrient requirements for infant formula respectively. Prompted 
by the    1986 Amendment, in 1989, the FDA established subpart E in 21 CFR part 
107
43; in 1991 the FDA implemented the provisions on record and record retention 
requirements by revising 21 CFR 106.100
44, as detailed below. 
However, the FDA to date has not fully responded to the 1986 Amendment in 
terms  of  establishing  good  manufacturing  practices.  The  FDA  proposed  a  set  of 
regulations  relating  to  “Current  Good  Manufacturing  Practices,  Quality  Control 
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38	 ﾠ Infant	 ﾠFormula	 ﾠRecall	 ﾠProcedures,	 ﾠ47	 ﾠFed.	 ﾠReg.	 ﾠ18,832	 ﾠ(Apr.	 ﾠ30,	 ﾠ1982)(to	 ﾠbe	 ﾠcodified	 ﾠat	 ﾠ21	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 ﾠ Infant	 ﾠFormula	 ﾠQuality	 ﾠControl	 ﾠProcedures,	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 ﾠFed.	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Procedures, Quality Factors, Notification Requirements, and Records and Reports, for 
the Production of Infant Formula” in 1996
45, but incredibly, it has not yet announced 
the final rules. Because of the complexity of infant formula manufacturing procedures 
and the continually advancing knowledge on best nutrients for infant formulas, the 
FDA has received abundant comments on the proposed regulations and has indicated 
that  integrating  all  of  these  recommendations  is  quite  cumbersome.  Thus,  after 
publishing the proposed regulations in 1996, the FDA reopened the comment period 
twice, and the last which ended 15th September 2006. Earlier 2012 the FDA had 
announced  that  it  had  planned  to  announce  the  final  rules  of  “Current  Good 
Manufacturing  Practice,  Quality  Control  Procedures,  Quality  Factors,  Notification 
Requirements, and Records and Reports, for the Production of Infant Formula.”
46   
As of end of February 2012, the FDA’s regulations on “infant formula quality 
control procedures” were still primarily based on the content of the Infant Formula 
Act of 1980, without being revised; Besides the FDA deferred to the infant formula 
industry’s  comments  to  a  great  extent  by  revising  the  proposal  to  remove 
“unnecessary  details”  and  to  eliminate  “unnecessary”  sampling  and  testing 
requirements.
47  With  regards  to  ingredient  controls,  if  an  ingredient  is  considered 
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generally stable on shipping and storage, or if a supplier guarantees that the nutrient 
composition has been analyzed, or if the formula is labeled as having a certificated 
nutrient  composition,  then  there  is  no  need  for  the  manufacturer  to  analyze  the 
ingredients before manufacture.
48  Thus, “a manufacturer may handle raw materials in 
any  reasonable  manner.”
49  Regarding  in-process  controls,  the  current  regulations 
require  the  infant  formula  manufacturer  to  implement  a  quality  control  system  to 
verify the addition of each ingredient
50, but the manufacturer maintains the flexibility 
to design a system most suitable to its needs.
51  Concerning product evaluation, the 
manufacturer has the authority to establish the criteria for sampling and testing each 
batch of infant formula prior to distribution.
52 
Under  subpart  C  of  21  CFR  part  106,  the  manufacturer  should  maintain  all 
records  pertaining  to  “food-packaging  material,”
53  “nutrient  premix  testing,”
54 
“compliance with proper quality control procedure,”
55  “required nutrients at the final 
product stage,”
56  “distribution of infant formula,”
57  “the microbiological quality and 
purity  of  raw  materials  and  finished  powered  infant  formula,”
58  “audit  plans  and 
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procedures,”
59  and a file regarding “infant formula complaints”
60. This subpart was a 
response to the 1986 Amendment aimed to ensure a safe, wholesome and sanitary 
source of nutrients for infants. On the other hand, in an effort not to unduly burden the 
manufacturers, the FDA specified that “infant formula manufacturers need not obtain 
from upstream companies and that infant formula manufacturer cannot be expected to 
obtain all premix testing records.”
61  In effect, the premix supplier holds the obligation 
to retain all records necessary to confirm the accuracy of premix certifications and 
guarantees of analysis.
62   
Under subpart B of 21 CFR part 107, the FDA specified that infant formula 
labels should contain: 1) a table nutrients; 2) a “use by” date; 3) a warning statement 
of  improper  preparation  and  use  of  infant  formula;  4)  a  statement  that  the  infant 
formula should be used as directed by physicians; and 5) directions for preparation 
and use.
63  The FDA does not require manufacturers to include bilingual directions for 
formula preparation and use, but requires manufacturers to use proper symbols and 
pictograms to illustrate the boiling, measuring, and mixing of water with a measured 
amount  of  concentrated  or  powered  infant  formula,  which  should  also  be 
understandable for consumers who do not speak English. As for ready-to-feed infant 
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formulas  (those  that  do  not  require  mixing  with  water),  only  more  essential 
information necessary for preparation and use is required on the individual containers, 
but the rest of information can appear on the outer label of the multiunit packages.
64   
In addition, the FDA established terms and conditions in the subpart C of 21 
CFR  part  107  under  which  formulas  geared  for  infants  with  special  medical  and 
dietary needs can be exempted from the requirements set by FDA. The FDA sorted 
exempted infant formulas by their availability at the retail level: manufacturers of 
exempt infant formula generally available at the retail level should comply with the 
requirements for nutrients, quality control procedures and labeling for regular infant 
formulas  established  by  the  FDA,  unless  specific  deviations  are  justified; 
manufacturers of exempted infant formulas generally not available at the retail level 
should establish an appropriate quality control procedure to ensure infant formula 
meets  applicable  nutrients,  including  any  special  nutritional  needs  for  the  specific 
disorders or conditions for which the formula is intended.
65 
In  order  to  comply  with  the  1986  amendment,  the  FDA  revised  its  recall 
requirement for infant formula in the subpart E of 21 CFR part 107 to:   
•  Specify  recall  procedures  that  should  be  used  by  manufacturers  in 
removing from the marketplace adulterated and misbranded infant formula 
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that the FDA had determined may present a risk to human health; 
•  Require a manufacturer recalling an infant formula that presents a risk to   
human  health  to  request  that  each  retail  establishment  at  which  infant 
formula is sold or available for sale post a notice of such recall; and   
•  Establish infant formula distribution records retention requirements.
66 
In sum, with respect to the administrative policy for infant formula, the FDA has 
become  stricter;  its  infant  formula  regulations  have  become  more  detailed  and 
stringent.  Along  with  this  trend,  the  upcoming  regulations  on  “Current  Good 
Manufacturing  Practice,  Quality  Control  Procedures,  Quality  Factors,  Notification 
Requirements, and Records and Reports, for the Production of Infant Formula” stand 
a good chance of containing more particulars. 
With  the  United  States’  regulatory  system  outlined,  we  now  examine  Taiwan’s 
regulatory scheme on infant formula. 
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Taiwan’s	 ﾠFood	 ﾠSanitation	 ﾠAct	 ﾠand	 ﾠRegulations	 ﾠon	 ﾠInfant	 ﾠFormula	 ﾠ
Taiwan’s	 ﾠFood	 ﾠSanitation	 ﾠAct	 ﾠ
Compared  to  the  legislative  history  of  infant  formula  in  the  United  States, 
Taiwan recognized the specific characteristics of infant formula relatively later. While 
Taiwan’s Congress passed the Food Sanitation Act in 17
th January 1973, it does not 
apply to infant formula. It took until May 2008 for Taiwan’s Congress to revise the 
Food Sanitation Act and add two clauses that give infant formula legal standing.
67   
However, the Food Sanitation Act defines “infant formula” only as a “special 
dietary food” that is nutritionally balanced or has added nutrients, to be consumed by 
people  with  special  nutrient  requirements
68;  it  delegates  Taiwan’s  Department  of 
Health to prescribe restrictions on the scope, methods and venues of advertising for 
special dietary foods.
69  The Food Sanitation Act, the only statute concerning infant 
formula, does not specify any nutrient or processing requirements. In other words, 
Taiwan still does not regard infant formula as a special category of food, as does the 
United States. Taiwan’s Food Sanitation Act treats infant formula as other food by 
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authorizing Taiwan’s Department of Health to establish regulations on the sanitation, 
safety and quality standards of infant formulas. 
 
Taiwan’s	 ﾠInfant	 ﾠFormula	 ﾠSanitation	 ﾠCriterion	 ﾠRegulation	 ﾠ 	 ﾠ
Based on Food Sanitation Act, TFDA was authorized by Department of Health to 
establish  Infant  Formula  Sanitation  Criterion  Regulation  on  2
nd  July  2009.
70  This 
regulation does not specify sanitation criteria in detail. Instead it solely sets a brief 
standard for the sanitation of infant formula, including the total number of bacteria 
allowed  in  the  standard  plate  count  procedure,  and  no  Escherichia  coli,  no 
Enterobacter sakazakii, no hormones, no antibiotics, no radioactive substances, no 
pesticides or pesticide residues, no aflatoxin, or any other foreign substances.   
 
TFDA	 ﾠordinances	 ﾠ 	 ﾠ
On 27
th December 2001, Taiwan’s Department of Health issued an ordinance 
requiring that all manufacturers of foods that are considered special dietary foods, 
including infant formula, register their products with TFDA. Under the regulation, 
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infant  formula  manufacturers,  among  other  manufacturers  of  dietary  supplements, 
such as vitamins, must acquire TFDA approval to register a new infant formula. To 
register, a manufacturer must submit the following documents: 1) an ingredient list; 2) 
a product specification report, 3) a nutrient analysis report; 4) an official certificate 
that shows the product is being sold or used by other countries, or related clinical trial 
reports of the product; 5) a copy of summarized diagram on manufacturing process; 6) 
a summary and diagram of the manufacturing process; 7) an official certificate issued 
by Ministry of Economic Affairs, R.O.C. that verifies the legitimacy of the original 
manufacturer;  8)  two  copies  of  the  label,  outer  package,  inserted  instruction  and 
Chinese  label  of  the  product;  9)  a  copy  of  the  applicant’s  [the  manufacturer’s] 
business license ; 10) a sample of the intact product.
71   
TFDA has created an online database that enables the public to look up whether 
an infant formula is approved by TFDA. As of February 23, 2012, 95 types of infant 
formula had been approved by TFDA, most of which are manufactured by foreign 
manufacturers.
72  As to the labeling of infant formula, TFDA designed a logo as Fig.1 
and ordered that all manufacturers of approved infant formulas place this logo, which 
contains  two  sentences  ―  “Breastfeeding  is  healthier  for  infants”  and  “The 
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Department of Health cares about you” ― on all packages and containers.
73  In 2003 
TFDA issued another ordinance prohibiting any retailer or manufacturer or wholesaler 
from advertising and promoting infant formula; it explained that this policy is aimed 
to encourage breastfeeding.
74 
 
Taiwan’s	 ﾠNational	 ﾠStandards	 ﾠon	 ﾠInfant	 ﾠFormula	 ﾠ
In contrast to the U.S.’s FDA, TFDA does not have the authority to establish 
standards  for  infant  formulas.  In  Taiwan,  the  Bureau  of  Standards  (BOS)  has  the 
power to set the standards (e.g., purity, nutrient content, manufacturing processes, and 
labeling) on infant formula. First, the BOS promulgated standards on infant formula 
in  1980  by  establishing  mandatory  infant  formula  criteria  including  “essential 
ingredients  and  quality  factors,”  “food  additives,”  “contaminants,”  “packaging”, 
“container,”  and  “labeling”.
75  Over  the  past  three  decades,  the  BOS,  referring  to 
Codex  Standard,  put  forth  by  the  Codex  Alimentarius  Commission,  revised  its 
standards in March 1984, March 1988, September 1988, August 1993, and November 
2008. 
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Comparison	 ﾠof	 ﾠthe	 ﾠU.S.	 ﾠand	 ﾠTaiwan’s	 ﾠLegal	 ﾠframework	 ﾠof	 ﾠInfant	 ﾠ
Formula	 ﾠ 	 ﾠ
Generally speaking, the United States has a comprehensive scheme of regulating 
infant formula, and Taiwan divides its regulations between TFDA and BOS.   
When the U.S. Congress enacted the Infant Formula Act of 1980, the U.S. FDA 
was assigned comprehensive authority to regulate the manufacture of infant formula, 
while TFDA and BOS share the authority of regulating the manufacture of infant 
formula. Under the U.S. regulatory model, infant formula manufacturers know who 
regulates  what  aspects  of  infant  formula,  and  if  they  have  questions  about  the 
regulations or want to make suggestions to improve the infant formula industry, they 
clearly know with whom to communicate. 
  In contrast, in Taiwan, manufacturers and distributors of infant formula face a 
bit  more  confusion  with  both  the  BOS  and  TFDA  sharing  the  authority  over  the 
manufacture, purity and safety of infant formula. On the one hand, Taiwan’s BOS 
borrows indiscriminately from the Codex Alimentarius Commission's experience to 
establish standards for infant formula, and on the other hand, TFDA has the duty not 25	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only  to  implement  the  standards  set  by  Taiwan’s  BOS  and  to  supervise 
manufacturers’  compliance  with  these  standards,  but  also  the  duty  to  oversee 
compliance  with  the  Infant  Formula  Sanitation  Criterion  Regulation  and  issue  the 
ordinances relating to labeling and promotion of infant formulas. However, the scope 
of TFDA’s authority is not well-defined. Sometimes infant formula manufacturers are 
not sure as to which authority regulates their products and to whom they should direct 
specific questions or complaints. On Nov. 26, 2010 TFDA announced on its official 
website that if the standards set by BOS are in conflict with any ordinances issued by 
TFDA,  the  ordinances  issued  by  TFDA  should  applied.  Nonetheless,  this 
announcement is not backed up or confirmed by BOS or any other government body 
so far. 
Moreover, since the U.S. FDA is the only agency with the power to establish 
regulations  and  to  implement  its  policy,  it  is  easier  for  the  FDA  to  identify  and 
remedy  the  pitfalls  of  its  regulations  and  close  any  loopholes.  However,  while 
Taiwan’s BOS enjoys the power to set the standards of “essential ingredients and 
quality  factors  of  infant  formula”,  “food  additives,”  “contaminants,”  “packaging,” 
“container,”  and  “labeling,”  TFDA  is  charged  with  carrying  out  the  standards  in 
practice. Hence, when TFDA discovers loopholes in the regulations and assumes the 
costs and endures the public pressure in executing the regulations, it has no authority 26	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to revise the standards. Consequently, TFDA must assume the burden of persuading 
the BOS to revise its standards, which though time-consuming and burdensome, is 
part of its official responsibilities.   
Further, in the United States infant formula enjoys a unique status of food. In this 
context, the U.S. FDA has a well-established, clear, and systematic framework to 
regulate all aspects of infant formula. Under 21 CFR part 106 and 107, the U.S. FDA 
specifies  required  quality  control  procedures,  records  and  reporting  systems, 
notification  requirements,  formula  labeling,  exemption,  nutrient  requirements  and 
recall processes and regulations. At the same time, infant formula has not yet become 
an independent category of food in Taiwan, but is classified under “special dietary 
foods”. In terms of establishing regulations and issuing ordinances, TFDA gives great 
weight to infant formula production sanitation standards, labeling and promotion of 
infant formula, but it fails to systematize all its regulations and ordinances. 
In  sum,  the  United  States  has  a  relatively  comprehensive,  clear  and  efficient 
framework to govern infant formula production, distribution, and marketing based on 
its legal authority and set of regulations. Taiwan’s regulatory system, in contrast, does 
not classify infant formula as a unique food category, though it does consider it a 
dietary  supplement.  In  effect,  Taiwan’s  infant  formula  regulatory  system  is  quite 
confusing for manufacturers. Furthermore, since Taiwan has two legal authorities that 27	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regulate infant formula, and scattered regulations, even more confusion results for 
manufacturers.   
Over  several  decades,  the  U.S.  FDA  transformed  its  regulatory  policy  from 
relatively loose, or weak control to stricter regulations that mandate compliance in all 
areas of formula manufacturing, marketing and labeling, while TFDA has chosen to 
address only a few major areas of infant formula. 
In  1982,  while  establishing  21  CFR  part  106,  TFDA  repudiated  its  own 
originally proposed regulations by eliminating some details in order to “permit each 
manufacturer to adopt the system that is best suited to its needs.”
76  In its proposed 
rules, the FDA expatiated on the sampling, testing, analysis, operations control, and 
recordkeeping for in-process and completed formulas, and required manufacturers to 
establish  an  acceptance  protocol  for  ingredients,  an  in-process  operational  control 
program,  and  a  finished  product  evaluation  system.
77  After  receiving  several 
comments from the infant formula manufacturers during the public comment period, 
the FDA agreed that the proposed rules required unnecessary details. Hence, the FDA 
revised the proposed rules by stating only the objectives without specifying how they 
should be achieved. 
The  1986  Amendment  was  a  turning  point  in  the  U.S.  FDA’s  regulatory 
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approach  to  infant  formula.  Dissatisfied  with  the  FDA’s  regulations  and 
implementation of the Infant Formula Act, Congress explicitly required that the FDA 
issue regulations establishing requirements for quality factors and CGMP, including 
quality control procedures, and it also tightened its infant formula recall requirements. 
Consequently, the subsequent rules established by the FDA contained more details 
and  were  more  stringent.  The  proposed  rules  of  “Current  Good  Manufacturing 
Practice, Quality Control Procedures, Quality Factors, Notification Requirements, and 
Records  and  Reports,  for  the  Production  of  Infant  Formula”  in  1996  is  a  good 
example  of  the  tightened  requirements  for  manufacturing  infant  formulas. 
Consequently,  this  change  of  regulatory  policy  reduced  the  industry’s  freedom  to 
design its own manufacturing, quality control and labeling regime and forced it to 
comply with stricter standards. 
In  contrast  to  the  U.S.’s  regulatory  tightening,  TFDA  embraced  a  skeleton 
method of addressing its rules. Infant Formula Sanitation Criterion Regulation set 
only sanitation goals without mandating any manufacturing best practices or quality 
control procedures. In addition, all the ordinances do no more than tell manufacturers 
what the standards are, rather than how to achieve those standards and they do not 
provide for the enforcement of these standards. Perhaps this outcome is due to the fact 
that Taiwan’s Congress and TFDA have chosen not to recognize infant formulas as a 29	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special food or unique food category as the United States has done. 
Although Taiwan has a weak infant formula regulatory system, it does not mean 
that the administration has decided to completely rely on industry self-regulation. For 
example,  despite  the  slim  rules,  TFDA  mandates  that  no  infant  formula  can  be 
marketed without TFDA analysis and approval of such infant formula. Thus, if a 
manufacturer wants to enter Taiwan’s infant formula market, it holds the burden of 
persuading TFDA that its infant formula meets all the standards set by TFDA. In 
contrast, in the United States, infant formula manufacturers are required to notify the 
FDA 90 days prior to marketing a new formula and submit written verifications that 
summarize test results demonstrating that its infant formula complies with specific 
FDA  requirements  after  its  first  production  batch  and  before  its  introduction  into 
interstate commerce. 
Following this analysis of infant formula regulatory systems in the United States 
and Taiwan, which approach is better for the welfare of infants remains inconclusive. 
On one hand, systematic and detailed regulations require manufacturers to meet the 
standards, ensuring the nutrient quality, safety and sanitation of infant formulas. On 
the other hand, it takes a longer time and more resources to collect comments; analyze 
the feasibility of the regulations; integrate different opinions and establish the rules. 
For instance, after the U.S. Congress passed the 1986 Amendment, it took the FDA 30	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almost  ten  years  to  propose  the  “Current  Good  Manufacturing  Practice,  Quality 
Control  Procedures,  Quality  Factors,  Notification  Requirements,  and  Records  and 
Reports, for the Production of Infant Formula”. And since the proposed rules was 
published in the Federal Registrar in 1996, the FDA reopened the comment period 
twice and so far the final rules have not yet been announced.     
In comparing the two nations’ approaches to regulating the manufacture of infant 
formula, it is evident that the United States assumes that people know what is best for 
their children and is careful not to intrude on manufacturers’ right to expression, but 
TFDA prioritizes public policy and to some extent restricts manufacturers’ right to 
express themselves.   
First,  in  the  United  States,  the  FDA  does  not  require  infant  formula 
manufacturers to place labels on formula stating that breastfeeding provides more 
health benefits than infant formula. During the comment period of 21 CFR Part 107 
Subpart  B,  some  suggested  that  there  should  be  a  label  on  formula  containers 
informing consumers that breastfeeding is recommended by physicians and offers the 
most  healthy  form  of  nourishment  for  infants.  The  U.S.  FDA  responded  that  no 
studies or data unequivocally find that infant formula labeling that states benefits of 
breastfeeding encourages the practice of breastfeeding or deters women from using 
formula.  In  addition,  requiring  a  statement  encouraging  breastfeeding  may  cause 31	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mothers who have decided not to breastfeed their infants to feel guilty or inferior 
because of their decision to use formula
78 
Although the fact that breast-milk contains the most suitable nutrients for infants 
prevailed in the U.S. when the Infant Formula Act was first established in 1980, the 
U.S. FDA was reluctant to mandate that such public information be required on infant 
formula containers sold in the United States. In strong contrast, in 2001, the TFDA 
issued  an  ordinance  requiring  formula  manufacturers  not  only  to  put  a  logo  (Fig. 
1)containing an image of a mother nursing a baby, but also to include “Breastfeeding 
makes infants healthier” and “The Department of Health cares about you” on the 
labels of every container of formula. In addition, TFDA in 2003 took a further step to 
promote  breastfeeding  by  restricting  the  promotion  or  advertisements  of  infant 
formulas  in  a  drugstores  or  and  retail  shops.  TFDA  thus  reflects  an  attitude  of 
paternalism to safeguard the nutrition for all infants. In comparison the U.S. seems 
more interested in protecting the infant formula industry.   
 
Conclusion	 ﾠ
U.S. regulation of infant formula manufacturing and sale has its unique history 
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and background, as does Taiwan’s case. Learning from the Syntex case, the U.S. 
Congress moved to acknowledge the unique characteristics of infant formulas, and 
gave  formula  a  separate  designation  than  other  foods.  And  responding  to  public 
opinion, Congress enacted the Infant Formula Act of 1980 and empowered the FDA 
to make and implement regulations to ensure that infant formula manufactured and 
sold  in  the  United  States  is  nutritious,  safe  and  manufactured  under  hygienic 
conditions. However, despite its wide ranging regulations and rules, the U.S. FDA 
appears to have confidence in the self-regulation of the infant formula industry and 
allows them to exercise their rights to expression.   
Without  a  tragedy  like  Syntex  to  prompt  Taiwan  to  regulate  infant  formula, 
Taiwan began promulgating regulations later compared to 1980 for the United States. 
Although it is hard to assess whether establishing rules in details is a necessary and 
efficient  way  to  safeguard  the  quality  of  infant  formula,  Taiwan  can  learn  some 
lessons from the United States, as the United States can also learn some lessons from 
Taiwan. In terms of Taiwan’s future challenges, constructing a more comprehensive 
and systematic framework of rules and having only one regulatory authority could 
help  Taiwan  to  better  address  how  best  to  safeguard  infant  formula  through 
regulations. On the other hands, the United States may rethink about its gradually 
decreased breastfeeding rate and ask the infant formula industry to inform the public 33	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that breast-milk contains the most suitable nutrients for infants, because the public 
entrusts the government with the power and even the duty to tell people what is best 
for them.   
  (Fig. 1) 